

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for September 2026

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp Sumatriptan/ Naproxen Sodium	Suvexx	SUMATRIPTAN & NAPROXEN SODIUM	85 mg & 500 mg	tablet	02566974
Auro Pharma Inc.	Auro-Bromfenac	Prolensa	BROMFENAC	0.07% w/v	solution (ophthalmic)	02540789
Pharmascience Inc.	PMS-Ivermectin	Rosiver	IVERMECTIN	1% w/w	cream (topical)	02557363
Eugia Pharma Inc.	Daptomycin for Injection RF	Cubicin RF	DAPTOMYCIN	500 mg/vial	powder for solution (intravenous)	02541920
Jamp Pharma Corporation	Jamp Doxepin Tablets	Silenor	DOXEPIN HCL	3 mg	tablet	02551330
Jamp Pharma Corporation	Jamp Doxepin Tablets	Silenor	DOXEPIN HCL	6 mg	tablet	02551349

Jamp Pharma Corporation	Metformin XR	Glumetza	METFORMIN HCL	500 mg	tablet (extended-release)	02567431
Jamp Pharma Corporation	Metformin XR	Glumetza	METFORMIN HCL	1000 mg	tablet (extended-release)	02567458
Pharmaris Canada Inc.	PRZ-ISMN	Imdur	ISOSORBIDE-5-MONONITRATE	60 mg	tablet (extended-release)	02562561